UNCOVER-3 5 Year Efficacy and Safety Manuscript Supplemental Materials
Published: 28 January 2021| Version 2 | DOI: 10.17632/rgrg58szs6.2
Contributor:
Description
Supplemental materials for "Long-term efficacy and safety of ixekizumab: 5-year analysis of the UNCOVER-3 randomized controlled trial" (JAAD-D-20-01565)
Files
Institutions
Eli Lilly and Co
Categories
Safety, Psoriasis, Efficacy Assessment, Efficacy Study